Known as APL-130277 the sublingual film is an on-demand, oral alternative for treatment of OFF episodes associated with Parkinson’s disease (PD) The phase 3 randomised, double-blind, placebo ...

today announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine sublingual film in the treatment of severe allergic reactions, including ...

In January of 2022, the FDA issued a drug safety communication about long term Suboxone sublingual film use and the increased risk of serious dental problems. FDA ordered that a new warning about ...

Aquestive Therapeutics (AQST) announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine ...

Maintenance phase: use buprenorphine/naloxone sublingual films at the same buprenorphine dose as Day 2; if intolerant to naloxone, may adjust buprenorphine by 2mg or 4mg increments/decrements to ...

today announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine sublingual film in the treatment of severe allergic reactions, including ...

Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and ...

About Anaphylm™ (epinephrine) Sublingual FilmAnaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage ...